Touch Ventures Limited (ASX:TVL) Announces 2024 Financial Results and Strategic Investments
Touch Ventures Limited (ASX:TVL) reports a $24.9M loss for 2024 and announces strategic investments in Tixel and Reshop.
Tag: Earnings Reports
Mirvac Group (ASX:MGR) Reports Half-Year Financial Results
Mirvac Group (ASX:MGR) reports a 2% revenue increase and a 100% profit rise for the half-year ended 31 December 2024.
FireFly Metals Ltd (ASX:FFM) Releases Interim Financial Results
FireFly Metals Ltd (ASX:FFM) reports a reduced net loss and increased assets for the three and six months ended 31 December 2024, highlighting financial stability and ongoing exploration activities.
Charter Hall Retail REIT (ASX:CQR) Releases 2025 Half Year Results
Charter Hall Retail REIT (ASX:CQR) announces a 7% decrease in operating earnings for 1H 2025, alongside strategic acquisitions and a stable distribution per unit.
GQG Partners (ASX:GQG) Reports 2024 Full Year Results
GQG Partners (ASX:GQG) reports a 26.9% increase in funds under management and a 46.9% rise in net revenue for 2024, alongside a 90% dividend payout ratio.
HealthCo Healthcare & Wellness REIT (ASX:HCW) Announces 1H FY25 Results
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
Meridian Energy Limited (ASX:MEZ) Releases January Operating Report
Meridian Energy Limited (ASX:MEZ) releases its January 2025 operating report, detailing hydro storage levels, retail sales trends, and generation performance.
WAM Capital Limited (ASX:WAM) Reports Strong Portfolio Performance and Maintains Interim Dividend
WAM Capital (ASX:WAM) outperforms key indices by up to 9.4%, declares a 7.75c interim dividend, driven by a robust investment portfolio.
AMP Limited (ASX:AMP) Announces FY24 Financial Results
AMP Limited (ASX:AMP) reports a 15.1% increase in underlying NPAT for FY24, alongside cost reductions and a final dividend declaration.
AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results
AVITA Medical (ASX:AVH) reports a 30% revenue increase in Q4 and FDA approvals, setting the stage for significant growth in FY 2025.